Blis Technologies confirms Asia-Pacific and Africa distribution agreement with iNova Pharmaceuticals
7 September 2018 | Dunedin, New Zealand
Blis Technologies Limited today confirmed it has entered into a distribution agreement with iNova Pharmaceuticals
(Singapore) Pte Ltd for the distribution of BLIS branded products. iNova Pharmaceuticals is a multinational
pharmaceutical and consumer health care company that markets and sells a wide range of market-leading products in over
20 countries across Asia-Pacific and Africa.
The agreement will provide iNova Pharmaceuticals with exclusive distribution rights for BLIS branded products across
Australia, Sub-Saharan Africa, and Asia based on a commitment of resources to support product launches. iNova
Pharmaceutical’s presence in pharmacy retail provides a strong platform for the launch of BLIS branded products into
overseas markets.
The initial focus will be on launch plans for the Australian market where BLIS K12 has achieved inclusion in TGA’s
Therapeutic Goods (Permissible Ingredients) Determination for use in listed complementary medicines, allowing stronger
positioning of the BLIS portfolio.
Blis CEO Brian Watson says that this agreement is another important step in the company’s finished product strategy.
“iNova Pharmaceuticals has a strong presence in the pharmacy channel and a proven track record of establishing
category-leading brands in consumer health care. Working with a partner of this calibre will provide the right
capability and resourcing to effectively establish BLIS branded products in multiple markets across the iNova
Pharmaceuticals network. Our focus initially will be to finalise our plans for the Australian market but also to
progress launch plans for other markets across Asia and Africa”
The agreement builds on the success of Blis Technologies’ new distribution relationship in New Zealand with Radiant
Health, which also holds the distribution rights for the iNova Pharmaceuticals product range locally. Radiant has
demonstrated its ability to leverage its presence in the market to help grow the BLIS range.
ENDS